Clinical Outcomes of Exenatide Versus Basal Insulin

CompletedOBSERVATIONAL
Enrollment

18,000

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

exenatide once weekly

patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator

DRUG

exenatide twice daily

patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.

DRUG

basal insulin

patients with basal insulin treatment under their standard care, no intervention was given by the study investigator

Trial Locations (1)

CF14 3QZ

Pharmatelligence, Cardiff

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT02987348 - Clinical Outcomes of Exenatide Versus Basal Insulin | Biotech Hunter | Biotech Hunter